TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. Here are ten companies with drugs facing FDA approval decisions in the first half of this year.
Drug/indication: Horizant for restless leg syndrome
Approval decision date: UnknownXenoport said that the FDA extended the Horizant approval decision date to Feb. 11 from Feb. 9 due to severe winter weather that shut down Washington. Yet the Feb. 11 deadline came and went without any word on the drug's approval. GlaxoSmithKline (GSK) is Xenoport's marketing partner for Horizant. Update: The FDA rejected Horizant Wednesday night, citing concerns about a potential link between the drug and pancreatic tumors in rats.